Literature DB >> 3355204

Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.

S De Virgiliis1, M Congia, M P Turco, F Frau, C Dessi, F Argiolu, R Sorcinelli, A Sitzia, A Cao.   

Abstract

High doses of intravenous desferrioxamine infused over a short period of time induce a large faecal and urinary iron excretion but also produce retinal abnormalities that are characterised by decreased amplitude on electroretinography and defective dark adaptation. This regimen also results in high faecal iron, zinc, and copper excretion, and reduced granulocyte zinc concentrations and alkaline phosphatase activity. The retinal abnormalities may be related to the zinc and copper deficiency and/or iron depletion 'per se' which interferes negatively with critical iron dependent enzymes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355204      PMCID: PMC1778769          DOI: 10.1136/adc.63.3.250

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  21 in total

1.  Continuous subcutaenous administration of deferoxamine in patients with iron overload.

Authors:  R D Propper; B Cooper; R R Rufo; A W Nienhuis; W F Anderson; H F Bunn; A Rosenthal; D G Nathan
Journal:  N Engl J Med       Date:  1977-08-25       Impact factor: 91.245

2.  Electrophoretic characterization of glucose-6-phosphate dehydrogenase (G6PD) in granulocytes and lymphocytes of normal and fava bean-sensitive subjects.

Authors:  G Fiorelli; G Idéo; L Alessio
Journal:  Clin Chim Acta       Date:  1969-07       Impact factor: 3.786

3.  The human electroretinogram in the light and during dark adaptation.

Authors:  E Auerbach
Journal:  Doc Ophthalmol       Date:  1967       Impact factor: 2.379

4.  Ferrioxamine excretion in iron-loaded man.

Authors:  M J Pippard; S T Callender; C A Finch
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

5.  Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.

Authors:  J H Graziano; A Markenson; D R Miller; H Chang; M Bestak; P Meyers; P Pisciotto; A Rifkind
Journal:  J Pediatr       Date:  1978-04       Impact factor: 4.406

6.  Abnormal dark adaptation in sickle cell anemia.

Authors:  J A Warth; A S Prasad; F Zwas; R N Frank
Journal:  J Lab Clin Med       Date:  1981-08

7.  Desferrioxamine administered intravenously by infusion causes a reduction in the electroretinogram in rabbits anaesthetized with urethane.

Authors:  G B Arden
Journal:  Hum Toxicol       Date:  1986-07

8.  The effect of severe zinc deficiency on the morphology of the rat retinal pigment epithelium.

Authors:  A E Leure-duPree; C J McClain
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-10       Impact factor: 4.799

9.  Response to long-term deferoxamine therapy in thalassemia.

Authors:  A Cohen; M Martin; E Schwartz
Journal:  J Pediatr       Date:  1981-11       Impact factor: 4.406

Review 10.  Zinc in the eye.

Authors:  Z A Karcioglu
Journal:  Surv Ophthalmol       Date:  1982 Sep-Oct       Impact factor: 6.048

View more
  19 in total

1.  Macular vitelliform lesion in desferrioxamine-related retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman; Anastasios Anastasakis; Martin Lindeman
Journal:  Doc Ophthalmol       Date:  2010-06-09       Impact factor: 2.379

2.  EOG as a monitor of desferrioxamine retinal toxicity.

Authors:  Rudy R Hidajat; Jan L McLay; David H Goode; Ruth L Spearing
Journal:  Doc Ophthalmol       Date:  2004-11       Impact factor: 2.379

Review 3.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

4.  Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2011-12-08

Review 5.  Deferoxamine (desferrioxamine). New toxicities for an old drug.

Authors:  Y Bentur; M McGuigan; G Koren
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

6.  Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine).

Authors:  K Sofroniadou; M Drossou; L Foundoulaki; K Konstantopoulos; D Kyriakoy; J Zervas
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 7.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 8.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.

Authors:  Maura Di Nicola; Giulio Barteselli; Laura Dell'Arti; Roberto Ratiglia; Francesco Viola
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

10.  Deferoxamine retinopathy: spectral domain-optical coherence tomography findings.

Authors:  Cheng-Hsiu Wu; Chao-Ping Yang; Chi-Chun Lai; Wei-Chi Wu; Yi-Hsing Chen
Journal:  BMC Ophthalmol       Date:  2014-07-02       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.